Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 5c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.94 -1%
Revenue Growth %: +17.5%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +17.5%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.03, $0.05 worse than the analyst estimate of $0.08. Revenue for the quarter came in at $46.06 million versus the consensus estimate of $62 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Nike names former Pfizer CFO David Denton as new finance chief
- BofA lists top 5 themes driving next $1tn in incremental semi sales
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
